Chimeric PvCSP Polypeptide for Broad Malaria Strain Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current malaria vaccines are inadequate in addressing Plasmodium vivax infections, as they often focus on a single protein and lack comprehensive coverage of the parasite's diverse strains, leading to limited protection and potential for vaccine resistance.
Innovation Solution
Development of novel polypeptides and DNA sequences based on the circumsporozoite protein of Plasmodium vivax, incorporating both common and variant allelic forms, fused with amino-terminal and carboxy-terminal regions, to elicit broad immune responses and provide protective immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current malaria vaccines target a single protein, then the vaccine structure is simple and easy to manufacture, but the protection coverage is limited and cannot address diverse parasite strains
Solution Approach 1:
The patent combines multiple PvCSP repeat regions (both common VK210 and variant VK247 allelic forms) into a single chimeric polypeptide structure. This merging of multiple antigenic targets into one vaccine molecule enables broad protection against diverse P. vivax strains while simplifying administration compared to multiple separate vaccines.
Solution Approach 2:
The chimeric polypeptide is designed to universally recognize both common and variant P. vivax CSP strains through incorporation of multiple repeat regions. This multi-functional design allows a single vaccine to provide broad-spectrum protection against genetically diverse parasite populations, addressing the limitation of strain-specific vaccines.
2Reliability
If vaccines incorporate multiple repeat regions and allelic forms, then the immune response coverage is enhanced, but the manufacturing complexity increases
Solution Approach 1:
The vaccine design segments the diverse P. vivax CSP antigenic regions into distinct repeat modules (VK210 and VK247) that can be independently characterized and assembled. This modular segmentation allows for systematic production and quality control while achieving comprehensive strain coverage through combination of standardized antigenic units.
3Adaptability or versatility
If the vaccine uses only common PvCSP sequences, then the manufacturing is straightforward, but it fails to protect against variant strains
Solution Approach 1:
The vaccine employs a composite polypeptide structure integrating both common (VK210) and variant (VK247) PvCSP repeat sequences. This composite design combines antigenic diversity from multiple strain types into a single molecular entity, providing broad strain coverage while maintaining a unified vaccine formulation that is manufacturable through recombinant expression systems.
Data Source
AI summary
Malaria in humans is caused by infection with Plasmodium species parasites including P. vivax. The biology and immunobilogy of P. vivax is distinct from that of P. falciparum. Provided are unique synthetic polypeptides and DNA molecules which encode them. Each of these molecules correspond to regions of the circumsporozoite protein of P. vivax. Each molecule comprises sequences corresponding to several repeats of the central region of the Pv 210 variant fused to sequences corresponding to several repeats of the central region of the Pv 247 variant. Each molecule additionally comprises sequences corresponding to either the amino terminus, the carboxy terminus, or both the amino and carboxy termini of the PvCSP. Also provided are vaccines comprising these unique sequences and methods of using these vaccines and sequences to prevent and treat Pv malaria.